Copyright
©The Author(s) 2024.
World J Hepatol. Mar 27, 2024; 16(3): 393-404
Published online Mar 27, 2024. doi: 10.4254/wjh.v16.i3.393
Published online Mar 27, 2024. doi: 10.4254/wjh.v16.i3.393
Table 2 Tumor, diagnosis, and treatment characteristics for cirrhotic hepatocellular carcinoma, n (%)
| Variable | BMI < 25 kg/m², (n = 654) | BMI 25.0-29.9 kg/m², (n = 767) | BMI ≥ 30 kg/m², (n = 841) | P value |
| Tumor size (cm) | 5.1 ± 4.2 | 4.2 ± 3.0 | 4.2 ± 3.2 | < 0.001 |
| AFP (ng/mL) category | ||||
| < 20 | 269 (43.7) | 399 (54.8) | 417 (51.9) | < 0.001 |
| 20-200 | 125 (20.3) | 164 (22.5) | 178 (22.1) | |
| > 200 | 221 (35.9) | 165 (22.7) | 209 (26.0) | |
| Tumor stage | ||||
| Single | 230 (35.2 | 331 (43.2) | 386 (46.0) | < 0.001 |
| 3 tumors < 3 cm | 88 (13.5) | 97 (12.7) | 116 (13.8) | |
| Large multinodular | 142 (21.7) | 173 (22.6) | 153 (18.2) | |
| Vascular invasion or extrahepatic spread | 193 (29.6) | 165 (21.5) | 184 (21.9) | |
| Anatomic stage | ||||
| Stage I | 173 (32.8) | 239 (41.0) | 293 (43.3) | < 0.001 |
| Stage II | 147 (27.9) | 169 (29.0) | 179 (26.5) | |
| Stage IIIA | 36 (6.8) | 38 (6.5) | 49 (7.2) | |
| Stage IIIB | 55 (10.4) | 38 (6.5) | 65 (9.6) | |
| Stage IIIC + IVA + IVB | 116 (22.0) | 99 (17.0) | 90 (13.3) | |
| Tumor outside of Milan criteria | 363 (55.6) | 370 (48.3) | 397 (47.3) | 0.003 |
| Tumor differentiation | ||||
| Well | 70 (27.1) | 109 (31.5) | 116 (32.6) | 0.15 |
| Moderate | 128 (49.6) | 175 (50.6) | 184 (51.7) | |
| Poor | 53 (20.6) | 59 (17.0) | 54 (15.2) | |
| Undifferentiated/anaplastic | 7 (2.7) | 3 (0.9) | 2 (0.5) | |
| How was HCC diagnosed? | ||||
| Part of screening | 236 (45.8) | 285 (48.6) | 350 (54.8) | 0.007 |
| Incidental | 120 (23.3) | 120 (20.5) | 116 (18.2) | 0.098 |
| Symptoms work up | 246 (47.8) | 244 (41.6) | 241 (37.7) | 0.003 |
| Evidence of screening within 2 years | 190 (36.8) | 259 (44.0) | 334 (52.1) | < 0.001 |
| Liver transplantation | 61 (9.3) | 134 (17.5) | 150 (17.8) | < 0.001 |
| Palliative care/hospice | 268 (41.0) | 271 (35.3) | 265 (31.5) | < 0.001 |
- Citation: deLemos AS, Zhao J, Patel M, Kooken B, Mathur K, Nguyen HM, Mazhar A, McCarter M, Burney H, Kettler C, Chalasani N, Gawrieh S. Lean body mass index is a marker of advanced tumor features in patients with hepatocellular carcinoma. World J Hepatol 2024; 16(3): 393-404
- URL: https://www.wjgnet.com/1948-5182/full/v16/i3/393.htm
- DOI: https://dx.doi.org/10.4254/wjh.v16.i3.393